Libtayo’s CSCC Label Expansion Broadens Practitioner Base

 
• By Alaric DeArment
  
Regeneron won FDA approval for Libtayo in adjuvant treatment of CSCC. (Alaric DeArment)

More from Immuno-oncology

More from Anticancer